Quantcast

Latest Memantine Stories

2014-07-24 23:02:33

New comprehensive report “Memantine - Comprehensive patent search” elaborated by Ark Patent Intelligence is now available at MarketPublishers.com. London, UK (PRWEB) July 24, 2014 Memantine was initially developed by Merz to treat Alzheimer’s disease (AD) and was first marketed in Germany under the brand name Akatinol; it was later licensed to Lundbeck Ltd. in Europe and other nations as Ebixa and in the USA to Forest Labs as Namenda. Lundbeck reported the sales of Ebixa of USD 420...

2014-07-21 12:25:38

Blockbuster Status Awaits Novel DMTs and Lundbeck/Otsuka's Emerging Symptomatic Agent Lu-AE58054, According to Findings from Decision Resources Group BURLINGTON, Mass., July 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, owing largely to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment. In 2023, these novel...

2014-07-02 23:03:21

MarketReportsOnline.com adds "Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs Analysis" report to its research store. Dallas, Texas (PRWEB) July 02, 2014 Alzheimer’s is a complex disease and there is no single “magic bullet” available in the market to prevent or cure it. Though many marketed drugs have been approved for Alzheimer’s disease, it still remains a significant area of unmet medical need. Clinical success has...

2014-05-23 08:24:08

BOSTON, Mass., May 23, 2014 /PRNewswire/ -- AZTherapies, Inc. a company developing novel treatments for Alzheimer's disease based on technology licensed from Massachusetts General Hospital, announced that it has received notice from FDA that it may proceed with the Phase III clinical study submitted in its IND application. This study is for its lead program, ALZT-OP1, a novel combination therapy for the prevention and treatment of early Alzheimer's disease. ALZT-OP1 is a...

2014-04-07 16:25:47

RnRMarketResearch.com adds "Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis" to its store. DALLAS, April 7, 2014 /PRNewswire-iReach/ -- Alzheimer's disease drug market is on the curvature stage. Since 2003, there is not any single "magic bullet" launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs...

2014-04-01 12:33:44

LONDON, April 1, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis Alzheimer's disease drug market is on the curvature stage. Since 2003, there is not any single "magic bullet" launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs....

2014-02-28 08:23:18

DUBLIN, February 28, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/l77qff/alzheimers ) has announced the addition of the "Concise Analysis of the International Alzheimer's Drugs Review, Alzheimer's Disease Drug Market" [http://www.researchandmarkets.com/research/l77qff/alzheimers ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Alzheimer's disease drug market is on the curvature stage....

2014-01-09 08:28:50

EMERYVILLE, Calif., Jan. 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. announced today that it has received $40 million in milestone payments from Forest Laboratories Holdings Limited (NYSE: FRX) for MDX-8704. MDX-8704 is a fixed dosed combination (FDC) of Namenda XR(®) (memantine HCl extended release capsules) and donepezil HCl being developed as a once daily therapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the United States. The...

2013-12-31 23:02:33

New research from the faculty of Icahn School of Medicine at Mount Sinai working with Veterans Administration Medical Centers suggests that alpha tocepherol, fat-soluble Vitamin E and antioxidant, may slow functional decline (problems with daily activities such as shopping, preparing meals, planning, and traveling) in patients with mild-to-moderate Alzheimer's disease and decrease caregiver burden. New York, NY (PRWEB) December 31, 2013 Difficulty with activities of daily living often...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.